TRT and Fertility: What Every Man Under 45 Needs to Know Before His First Injection

Testosterone replacement therapy is being prescribed faster than at any point in modern medicine. Between 2019 and 2024, U.S. prescriptions climbed from roughly 7.3 million to over 11 million, and the steepest growth has been in men ages 35–44 — the years when most men who want to start a family still haven’t.

Here is the part the TikTok ads almost never mention: standard TRT shuts down the signal your body uses to make sperm. For a meaningful percentage of men, that means temporary or, occasionally, lasting infertility. The conversation we are writing this article to start is the one most men only have after their first injection — when a fertility specialist tells them their sperm count is zero.

If you are considering TRT and you are not absolutely certain you are done having biological children, the rest of this article is for you.

Sperm production depends on a hormone signal that originates in the brain, not in the testicles. The hypothalamus releases GnRH, which tells the pituitary to release LH and FSH, which in turn tell the testes to make testosterone inside the testes and to mature sperm. This is the hypothalamic-pituitary-gonadal (HPG) axis.

When you inject testosterone from the outside, your brain reads the high level in your blood and assumes the system is fully on. So it turns the signal off. LH and FSH drop, sometimes to nearly undetectable levels. Intratesticular testosterone — the local, much higher concentration that actually drives spermatogenesis — collapses. The testes shrink. Sperm production falls.

The clinical literature is consistent on the rate: most men on standard TRT develop severe oligospermia or full azoospermia (zero sperm in the ejaculate) within three to six months, with reported rates of roughly 40–80% across studies depending on dose, duration, and individual response. A 2025 clinical guide in the Asian Journal of Andrology on testosterone-induced azoospermia frames this as one of the most common reversible-but-not-always-reversible causes of male infertility a urologist sees today.

A common assumption — repeated frequently in online TRT communities — is that you can simply stop testosterone and your fertility will come back. That is sometimes true. It is not reliably true.

Recovery of spermatogenesis after stopping exogenous testosterone is variable, slow, and incomplete in a meaningful minority of men. Published cohort data and the 2025 Asian Journal of Andrology review describe typical recovery on the order of several months to two years, with a small but real subset — around 5% in the most-cited series — who do not fully recover sperm production even with appropriate medical management. Risk factors for incomplete recovery include longer duration of use, higher doses, older age at TRT initiation, and use of multiple anabolic agents.

There is no test you can run before starting TRT that tells you which group you’ll be in. That uncertainty is the reason fertility-preserving protocols exist — and the reason the AUA’s 2024 Testosterone Deficiency Guideline recommends against prescribing testosterone monotherapy for men who want current or future fertility.

Three medication categories matter in this conversation. None of them are widely advertised, all of them require a clinician who knows the protocols, and the right answer depends on your timeline and goals.

HCG (human chorionic gonadotropin) mimics LH at the testicular receptor. That keeps the testes producing intratesticular testosterone — and therefore sperm — even when your brain has stopped sending its own LH signal. It can be used as a monotherapy in some men, or co-prescribed alongside testosterone to blunt the suppression. Typical fertility-protective dosing in the published literature is around 500 IU subcutaneously two to three times per week, with adjustments based on labs. The 2024 AUA guideline notes that concomitant low-dose hCG with testosterone can sustain intratesticular testosterone and spermatogenesis, though it stops short of recommending it as standard practice for all fertility-concerned men.

Enclomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus. Translated: it tricks the brain into thinking estrogen is low, so the brain turns LH and FSH back up, and the testes make their own testosterone. Because the signal is preserved, sperm production is preserved in roughly 80% of responders in the published trials. Enclomiphene is not currently FDA-approved as a finished drug product for male hypogonadism in the United States. Development by Repros Therapeutics stalled in 2015 when the FDA found the Phase 3 design inadequate, and the program has not been revived. Prescribing today happens through compounding pharmacies under physician supervision — legal, common, but a category patients should understand is “off-label / compounded,” not “FDA-approved tablet.”

Clomiphene citrate — enclomiphene’s older, mixed-isomer cousin — is FDA-approved for female infertility and used off-label in men for the same mechanism. It is a more established option than enclomiphene in many practices, with decades of off-label men’s-health use.

For some men — particularly those who want to become fathers within the next 6–12 months — the best protocol is often not TRT at all, but enclomiphene or clomiphene alone, or hCG monotherapy, which can raise testosterone meaningfully while keeping the fertility signal intact.

If you are 32, you have a partner, and you are open to having a child in the next five years, the calculation looks like this:

• Monotherapy TRT (testosterone alone, no fertility coverage): expect a 40–80% chance of azoospermia within 6 months. Recovery after stopping is likely but not certain, and may take 6 months to 2 years.
• TRT with concurrent hCG: intratesticular testosterone is preserved, and the published data support meaningful preservation of sperm production. This is the protocol the AUA acknowledges, with the caveat that evidence is still evolving.
• Enclomiphene or clomiphene monotherapy: avoids exogenous testosterone entirely. The brain keeps signaling, the testes keep producing, and fertility is generally preserved. Effective for men whose hypogonadism is “secondary” (brain-pituitary) rather than primary testicular failure.
• Sperm banking before TRT: the simplest, most reliable insurance policy. A few hundred dollars and an hour of your time, regardless of which medication path you choose.

None of these decisions are emergencies. Hypogonadism that has been present for months will not become catastrophic in the two weeks it takes to bank sperm or to add hCG to a protocol.

Done well, a fertility-aware TRT consult includes: a full hormonal panel (total and free testosterone, LH, FSH, SHBG, estradiol, prolactin), a conversation about whether you want children in the future, a discussion of the specific options above — including the option not to start TRT yet — and, if you decide to proceed, either a co-prescribed fertility-preserving medication or a clear plan to bank sperm first.

It also includes follow-up labs. Intratesticular testosterone can’t be measured directly in clinic, but LH, FSH, and a semen analysis at the 3–6 month mark tell you whether the protocol is working. If sperm counts are dropping despite hCG, the protocol gets adjusted. If you change your mind about future fertility, the conversation changes.

What it does not include is being shipped testosterone after a single online questionnaire and a single lab draw. That model is fast, cheap, and the reason r/Testosterone has thousands of posts from men who only learned about the fertility piece in retrospect.

It isn’t saying testosterone replacement therapy is bad. For symptomatic men with confirmed hypogonadism, properly prescribed TRT can be a significant quality-of-life intervention. It also isn’t saying every man under 45 should refuse TRT — many men in this age range have already completed their families, or have decided they aren’t going to have children, and for them the fertility risk isn’t relevant.

It is saying that the decision to start TRT and the decision about future fertility are the same decision, and they should be made together, before the first injection, with a clinician who is willing to name the trade-offs out loud.

If you are weighing TRT and the fertility piece hasn’t come up — or it came up and got brushed past — that’s the conversation worth having before you fill the prescription. Carolyn Pampalone, MSN, FNP-BC, has spent nearly two decades in hormone care, and at Naya Wellness our TRT protocols include HCG support when fertility is on the table. You can talk it through at our Chatsworth or Santa Barbara clinics, or by telehealth across California.

Two California locations and statewide telehealth — click a card to view details, or call to schedule a consult.